Trace Neuroscience
Trace Neuroscience is dedicated to developing treatments for neurodegenerative diseases such as ALS. The company focuses on genomic medicine and has recently launched with significant funding to expand its research and development efforts.
Industries
biotechnology
health-care
life-science
Nr. of Employees
small (1-50)
Trace Neuroscience
South San Francisco, California, United States, North America
Products
Splice‑switching antisense oligonucleotide candidate targeting UNC13A
A splice‑modulating ASO designed to correct disease-associated cryptic exon inclusion in UNC13A and restore synaptic function in experimental systems.
Splice‑switching antisense oligonucleotide candidate targeting UNC13A
A splice‑modulating ASO designed to correct disease-associated cryptic exon inclusion in UNC13A and restore synaptic function in experimental systems.
Services
Preclinical R&D programs for RNA-targeted genetic medicines in ALS
Discovery, design, and preclinical evaluation of RNA-targeting therapeutic candidates for ALS, including splice-modulating ASOs and mechanistic validation studies.
Preclinical R&D programs for RNA-targeted genetic medicines in ALS
Discovery, design, and preclinical evaluation of RNA-targeting therapeutic candidates for ALS, including splice-modulating ASOs and mechanistic validation studies.
Expertise Areas
- Genomic medicine for neurodegenerative diseases
- RNA-targeted therapeutics (antisense/splice-switching oligonucleotides)
- Target discovery and validation in ALS
- Preclinical translational neuroscience
Key Technologies
- Antisense oligonucleotides (ASOs)
- Splice-switching oligonucleotides
- Transcriptomic analysis of cryptic exons
- RNA biology and splicing assays